TY - JOUR T1 - Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation JF - Anticancer Research JO - Anticancer Res SP - 205 LP - 209 DO - 10.21873/anticanres.15474 VL - 42 IS - 1 AU - RYO TOYA AU - TAKAHIRO WATAKABE AU - DAIZO MURAKAMI AU - TOMOHIKO MATSUYAMA AU - TETSUO SAITO AU - YOSHIYUKI FUKUGAWA AU - KOHEI NISHIMOTO AU - YORIHISA ORITA AU - NATSUO OYA Y1 - 2022/01/01 UR - http://ar.iiarjournals.org/content/42/1/205.abstract N2 - Background/Aim: We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation. Patients and Methods: Twenty-five patients underwent TPF-CCRT without elective nodal irradiaion (ENI). After the RT of 40 Gy, five patients (20%) without tumor regression underwent surgery. Others underwent RT with a median total dose of 66 Gy. Results: Of the five patients who underwent surgery after the RT of 40 Gy, two showed residual carcinoma pathologically and the other three were confirmed to have complete pathological response to the treatment. The 5-year local control rate was 87%. No patients exhibited regional failure. No acute toxicities of grade 5 or late toxicities ≥grade 3 were observed. Conclusion: TPF-CCRT provides excellent tumor control with acceptable toxicities. CCRT while omitting ENI is a reasonable approach for T3 N0 glottic carcinoma without vocal cord fixation. ER -